Blockchain Registration Transaction Record

Aptevo's AML Therapy Shows 86% Benefit Rate, No CRS in Trial

Aptevo's mipletamig shows 86% clinical benefit rate in AML trial with no cytokine release syndrome. New data suggests potential to enhance frontline treatment for older patients.

This development matters because AML remains one of the most aggressive and difficult-to-treat blood cancers, particularly for older patients or those with comorbidities who cannot withstand intensive chemotherapy. Current treatment options for this vulnerable population are limited and often come with significant toxicity that compromises quality of life. The combination of high remission rates (79%) with MRD-negative status in over half of responders, coupled with the absence of cytokine release syndrome—a common side effect that frequently derails immunotherapy treatments—represents a potential paradigm shift. If these results hold in larger trials, mipletamig could offer a more tolerable yet effective treatment option that keeps patients on therapy longer, potentially extending survival and improving outcomes for thousands diagnosed annually with this devastating disease.